Cambridge Cognition, a leader in digital brain health assessment solutions, and The Michael J. Fox Foundation for Parkinson’s Disease Research are collaborating on the Parkinson’s Progression Markers Initiative (PPMI).
The PPMI will leverage Cambridge Cognition’s CANTAB cognitive assessments to characterize the cognitive profiles of Parkinson’s Disease patients. This initiative aims to unravel the mechanisms of the disease, trace its origins, and develop potential interventions to halt its progression.
PPMI includes individuals diagnosed with Parkinson’s disease within two years of symptom onset, offering a window into its early stages and neurological changes. CANTAB assessments will be utilized to assess 5,000 patients, providing valid and objective insights into their cognitive functions. These user-friendly assessments capture impairments in attention, executive function, memory, and visuospatial skills.
CANTAB assessments have been extensively utilized in Parkinson’s disease clinical trials, serving as targets for treatment development and evaluating new drug safety and efficacy. Cambridge Cognition’s CEO, Matthew Stork, expressed pride in the collaboration, highlighting the sensitivity of CANTAB assessments to disease progression.
Cambridge Cognition offers digital health solutions to advance brain health understanding and treatment. Their products assist in clinical trial optimization, early disease detection, and healthcare efficiency improvement.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
